0.05) compared with the results of PCR ASP genotyping.The consistency between FCM and PCR ASP genotyping was 88% for positive results,100% for negative results,with a total of 95.9%.Conclusion Flow cytometric HLA B 27 typing is rapid and sensitive and can be used together with PCR technique for diagnosis of some diseases such as ankylosing spondylitis.

Objective To understand the molecular genetic basis of Ael subgroup of ABO blood group system in the Han nationality.Method 2 Ael individuals were defined by standard blood group serological techniques,and genomic DNA was prepared for PCR SSP genotyping.Primers were designed and synthesized to amplify complete exon 6 and 7 including flanking intron sequence,and direct sequencing of gel purified PCR amplified fragments was performed using Bigdye Sequencing kit.Result A possibility of regarding the Ael allele as A2,B,O1 and O2 genes had been eliminated by the PCR SSP assay.According to the sequence analysis,Ael gene had 2 mutations of which one was a nucleotide substitution at position 532 in intron 5 (C to T),and the other was a single nucleotide(G) insertion at position 798 to 804 in exon 7 which alter the 86 amino acids sequence of the glycosyltransferase and furthermore extend the translated proteins by 37 amino acids compared with A1 allele.Conclusion The mutations of (789 804)G insertion and C(I 5/532)T substitution is the molecular genetic basis for Ael phenotype.

Objective To investigate the molecular basis for Jk(a b ) phenotype.Methods Routine serologic testing for phenotype.Genomic DNA covering 4～11 exons and partial introns of JK gene was amplified by ploymerase chain reaction.The PCR products were excised and purified from agarose gels with a kit,then fragments were directly sequenced.Results G mutated to A in the 3'acceptor splice site of intron 5;A to G at 78 site from the 3'end of intron 3;C to T at 84 site from the 5'end of intron 8; A to G at 588 site of exons ( exon 7); G to A at 838 site of exons (exon 9).The splice site mutation (G→A) of intron 5 may cause the skipping of exon 6.Conclusion G to A mutation in the 3'acceptor splice site of intron 5 maybe one of the molecular basis for Jk(a-b-) phenotype

Objective To identify the p phenotype. Method P blood group system was identified using p phenotype cells,anti PP 1 P k antiserum,and direct DNA sequencing.Result and Conclusion Proband was typed as p, with rare anti PP 1 P k in the serum,family study suggested that inheritance was autosomal recessive.

Objective To identify para-Bombay phenotype AB h m. Method ABO and H phenotype were typed. Absorption and elution were performed. Saliva was tested by inhibitory reaction. Direct sequencing was performed and family study was done. Results Proband was typed as rare para-Bombay phenotype AB h mand anti-H was detected in his serum. Family study suggested that the inheritance was autosomal recessive. Conclusion Rare AB h m phenotype was identified and anti-H has been detected in his serum.

Background and purpose:CA-125 is already recognized as one of the biomarkers for ovarian cancer.The serum CA-125 also had some significance in terms of the diagnosis and determination of the prognostic values for lung cancer.The purpose of this study was to investigate the effect of traditional Chinese medicine(TCM)therapy on serum CA-125 level in lung cancer patients.At the same time,we investigated the relationship between the serum CA-125 level and the clinical stages as well as the pathological types.Methods:Serum CA-125 levels from 30 normal donors were detected and compared to 60 patients with lung cancer by microparticle enzyme immunosorbant assay(MEIA).Results:Serum CA-125 levels in lung cancer group were(91?45)and significantly higher than those in healthy control group(18?5)(P

Objective To study the expressions of epithelial symbol factors including E-cadherin,?-catenin,and ?-catenin related to epithelial-mesenchymal transition(EMT) in C57 mice Lewis lung cancer and its mRNA expression affected by Feiyanning Decoction(Decoction for lung cancer).Methods The Real-Time PCR method was adopted to observe the E-cadherin,?-catenin,?-catenin mRNA expression of C57 mice with transplanted tumor in the right armpit and distal metastases and the affection of Feiyanning Decoction on the expression.Results The lung transplanted rate in the Feiyanning group was clearly lower than that in the model group(P

Objective To define the role of HCV-specific cytotoxic T lymphocytes (CTL) in chro-nic hepatitis C virus (HCV) infection. Methods HCV-specific CTL activity (HCV-CTL) was assessed in the liver and peripheral blood cells in 62 patients with chronic hepatitis C and 8 non-HCV-infection controls by using bulk-expanded liver/peripheral blood mononuclear lymphocytes (PBMC)-derived CD8+ cells as effector cells, EBV-transformed B cells as autologous target cells and recombinant vaccinia vectors expressing various regions of the HCV genome as transduction vector, in a standard chromium release assay. Results HCV-CTL activity was detected from the liver in 28 of the 60 patients (46.7%), but not from PBMC. CTL activity could not be detected from the liver and PBMC in all non-HCV-infection controls. Five patients with non-type 1 HCV infection were found to have HCV-specific CTL activity against HCV type 1 epitope. Compared with the patients without detectable HCV-specific CTL activity based on our assay, those exhibiting CTL activity had higher serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, higher histologic activity indices and lower levels of HCV RNA (all P

Objective To evaluate HBeAg quantification in predicting the efficacy of pegylated interferon (PegIFN) α treatment for patients with HBeAg-positive chronic hepatitis B (CHB).Methods A total of 216 HBeAg-positive CHB patients admitted in Ningbo No.2 Hospital during March 2009 and December 2011 were enrolled in the study.All patients were given subcutaneous injection of PegIFNα-2a or PegIFNα-2b weekly for 48 weeks and followed up for 24 weeks after discontinuation.Patients were divided into HBeAg seroconversion group and non-seroconversion group at the end of the follow-up.Receiver operating characteristic (ROC) curves were used to evaluate HBeAg levels at baseline and 12,24 weeks of treatment in predicting HBeAg seroconversion.Results HBeAg seroconversion was observed in 31.48％ (68/216) patients at the end of follow-up,and there was no significant difference in seroconversion rate between patients treated with PegIFNα-2a and those with PegIFNα-2b (32.00％ vs.29.27％,P ＞ 0.05).There was significant difference in baseline HBeAg levels between patients with HBeAg seroconversion and those without HBeAg seroconversion (Z =-3.834,P ＜ 0.05).HBeAg seroconversion patients had a tendency of rapidly decreasing HBeAg level,but there was no significant difference in decreasing rate between seroconversion and non-seroconversion patients (F =3.321,P ＞ 0.05).ROC curves showed that HBeAg level at 24-week was the best indicator for predicting HBeAg seroconversion with area under curve of 0.861.Conclusion Serum HBeAg level at 24-week of treatment may be used to predict the HBeAg seroconversion in HBeAg-positive CHB patients treated with PegIFNα.

Objective To investigate the efficacy of polyethylene glycol (PEG)-interferon α (PEG-IFNα) in treating HBeAg-positive chronic hepatitis B (CHB) and explore the relationship between hepatitis B virus (HBV) genotypes and the effect of interferon α (IFNα) therapy.Methods A total of 199 CHB patients with known genotypes were given subcutaneous injection of PEG-IFNα-2a or PEG-IFNαt-2b once a week for 48 weeks,with another 24 weeks follow up.The seroconversion of HBeAg influenced by HBV genotypes were analyzed after discontinuation of treatment.Results In local area,genotype C was the major genotype[64.32％ (128/199)].Except serum ALT and AST level,the differences in gender,age,liver inflammation,degree of liver fibrosis,HBeAg level and HBV DNA level between genotype B and C were not statistically significant(all P ＞0.05).The seroconversion rate of HBeAg in patients with genotype B at early stage of therapy (3 months) was significantly higher than that of patients with genotype C [26.76％ (19/71) vs 10.16％ (13/128),x2 =9.330,P =0.002].While at the end of follow-up,seroconversion rate of HBeAg in patients with genotype B (followed up for 6 months) was higher than that of patients with genotype C [39.44％ (28/71) vs 30.47％ (39/128)],but the difference was not statistically significant(x2 =1.645,P =0.200).By univariate analysis based on log-rank test,the time of HBeAg seroconversion in patients with genotype B was much earlier than that of genotype C [(13.99 ± 0.67) months vs (15.47 ± 0.41)months],but the difference was not statistically significant (P =0.150).Conclusions The seroconversion rate of HBeAg in patients with genotype B treated with PEG-IFNα was significantly higher than that of genotype C in early stage of therapy (3 months),while similar at the end of therapy.